Healthcare entity
Every one of those 1 sits in a single category, funding. ALTO-100 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 3 original sources on average, compared with 2.4 for the broader beat in this window.
Last mentioned: Mar 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, funding. ALTO-100 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 3 original sources on average, compared with 2.4 for the broader beat in this window. The 6 average consequence score is above the beat benchmark of 5.8 in the same window. We currently track 1 Healthcare story that mention Alto Neuroscience, all published on March 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Alto Neuroscience. Shared-story counts are live from our verified record — not editorial picks.
Expected Data Readouts
Anticipated primary endpoint results for the ALTO-100 Phase 2b/3 study in MDD.
$120M Private Placement
CFO Nick Smith announces a major financing round to accelerate late-stage clinical programs.
Phase 2b Expansion
Company expands clinical trials for ALTO-100 targeting specific biotypes of depression.
Initial Public Offering
Alto Neuroscience goes public on the NYSE to fund its precision psychiatry platform.
Alto Neuroscience has successfully raised $120 million through a private placement financing to accelerate its clinical-stage pipeline of precision medicines for mental health. Led by CFO Nick Smith, the funding underscores investor confidence in the company's AI-driven approach to identifying biomarkers for psychiatric disorders.
Source: Nyse (us) · Quartz Staff (us)
Alto Neuroscience is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
